Positive results from the second of two phase III trials set Compass Pathways plc’s synthetic psilocybin treatment, COMP-360, on track for a potential U.S. FDA approval within a year as the first classic psychedelic cleared for treatment-resistant depression. Read More
Ocular Therapeutix Inc.’s wet age-macular degeneration candidate, Axpaxli, beat anti-VEGF therapy Eylea (aflibercept) from Regeneron Pharmaceuticals Inc. in the phase III head-to-head trial called Sol-1, but not by enough of a margin for Wall Street. Shares of the firm (NASDAQ:OCUL) closed Feb. 17 at $6.99, down $1.89, or 21%, as investors mulled the top-line findings. Read More
Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion in a move to strengthen its diagnostics business. Under the terms of the agreement, Danaher will acquire all the outstanding shares of Masimo for $180 per share in cash, representing a 38.3% premium to Masimo’s last closing price. Read More
Newco Vesalic Ltd. has formed to take forward research indicating extracellular vesicles secreted by skeletal muscle cells carry toxic payloads that are key drivers of motor neuron diseases, including amyotrophic lateral sclerosis. The discovery of this process, which is largely external to the brain and the central nervous system, has opened up new targeting possibilities, and Vesalic is now working on in vivo studies to demonstrate preclinical proof of concept. Read More
A project that started as a bioreactor to assist astronauts in deep space to keep medications safe in a microgravity environment could help pharma companies model how drugs behave in the human body. Omnigeniq unveiled at the J.P. Morgan Healthcare conference the first computer model of a human protein as it exists in the body, confirming that native protein topology can be calculated directly from physics. Read More
Though it’s largely viewed by analysts as a simple delay rather than a setback, Disc Medicine Inc.’s unexpected complete response letter (CRL) for bitopertin in the rare genetic disorder erythropoietic protoporphyria (EPP) raises more questions regarding consistency and stability at the U.S. FDA. Read More
The variety of organoids that can be developed in vitro is enabling major advances. Depending on the type of tissues and the research goals, these small 3D cell-based structures that mimic real tissue offer certain advantages over animal models. Scientists at the University of Padova in Italy have created human neuromuscular organoids to reproduce cancer-induced muscle cachexia, a condition that murine models do not accurately replicate. Read More
Med-tech M&A activity opened 2026 at a slower pace, with January deal value totaling $665.33 million, coming in well below the 2025 monthly average of $3.51 billion and trailing most individual months last year. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Amicus, Biomarin, Coherus, Evommune, Galecto, Immunic, Nasus, Okyo, Opus. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Genfit, HCW, Ipsen, Median, Tempus AI, Ultragenyx, WY. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Applied Medical Technology, Eye Pcr, Hanchorbio, Invera Medical, Medtronic, PTC, Sumitomo. Read More
